Document Detail


Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
MedLine Citation:
PMID:  18327839     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Pulmonary arterial hypertension (PAH) is a progressive disease marked by vasoconstriction and vascular remodeling within pulmonary arteries leading to right heart failure and death. Significant advances in understanding the pathobiology of the disease have identified three key pathways involved in progression of this disease, which are the endothelin pathway, the prostacyclin pathway, and the nitric oxide/cyclic guanosine monophosphate pathway. Echocardiogram is the best screening tool to obtain an estimation of the pulmonary artery systolic pressure but right heart catheterization remains the standard by which the diagnosis is made. There are currently six FDA approved therapies for PAH. The mechanistic rationale, evidence behind their use and side effect considerations in utilizing these therapies in PAH patients will be the focus of this review.
Authors:
Myung H Park
Related Documents :
12438669 - Vascular endothelial growth factor causes pulmonary vasodilation through activation of ...
10477839 - Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension.
19329719 - Immediate clinical and haemodynamic benefits of restoration of pulmonary valvar compete...
18771769 - Numerical investigation of regurgitation phenomena in pulmonary arteries of tetralogy o...
21892979 - Are arterial blood gases necessary in the evaluation of acutely dyspneic patients?
8044939 - Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  71     ISSN:  1522-726X     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-03-10     Completed Date:  2008-04-10     Revised Date:  2013-06-18    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-13     Citation Subset:  IM    
Copyright Information:
Copyright 2008 Wiley-Liss, Inc.
Affiliation:
Division of Cardiology, Director of Pulmonary Vascular Disease Program, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA. mpark@medicine.umaryland.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use
Cardiac Catheterization
Disease Progression
Drug Therapy, Combination
Endothelium, Vascular / physiopathology
Epoprostenol / analogs & derivatives,  therapeutic use
Heart Failure / etiology
Humans
Hypertension, Pulmonary / classification,  diagnosis*,  drug therapy*,  physiopathology
Iloprost / therapeutic use
Isoxazoles / pharmacology
Phosphodiesterase Inhibitors / pharmacology
Piperazines / pharmacology
Platelet Aggregation Inhibitors / therapeutic use
Prognosis
Pulmonary Artery / physiopathology
Purines / pharmacology
Receptors, Endothelin / antagonists & inhibitors
Sulfonamides / therapeutic use
Sulfones / pharmacology
Thiophenes / pharmacology
Vasoconstriction / physiology
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Isoxazoles; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Platelet Aggregation Inhibitors; 0/Purines; 0/Receptors, Endothelin; 0/Sulfonamides; 0/Sulfones; 0/Thiophenes; 0/sitaxsentan; 0/treprostinil; 35121-78-9/Epoprostenol; 3M7OB98Y7H/sildenafil; 78919-13-8/Iloprost; Q326023R30/bosentan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacological options for inducing maximal hyperaemia during studies of coronary physiology.
Next Document:  Balloon assessment of patent foramen ovale morphology and the modification of tunnels using a balloo...